Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amplify Cybersecurity ETF (HACK) vs Heron Therapeutics Inc (HRTX) Price & Performance

Amplify Cybersecurity ETFTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Amplify Cybersecurity ETF vs Heron Therapeutics Inc — how do they compare? Amplify Cybersecurity ETF trades at $118.71, while Heron Therapeutics Inc trades at $0.32 (market cap $63.41M). The key difference: Amplify Cybersecurity ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

HACKHRTX
Sector
Sector/ThematicHealth
52-Week High
$119.19$1.49
52-Week Low
$70.69$0.33
Market Cap
$63.41M
Enterprise Value
$161.31M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amplify Cybersecurity ETF

HACK is trading at $115.42, up 1.97% with strong bullish momentum from moving averages. The ETF recently hit a 52-week high and is positioned to benefit from escalating cybersecurity spending, which is forecast to exceed $300 billion in 2026. Technical indicators show the stock is near resistance at $116 with RSI suggesting mild overbought conditions. Institutional interest is growing, with D.A. Davidson increasing its position by 44.8% in Q1 2026.

The outlook remains positive as AI-driven cyber threats fuel demand for cybersecurity solutions. Key risks include market volatility and competitive pressures from other cybersecurity ETFs. Analyst sentiment is bullish with the ETF capturing the full cybersecurity stack as enterprises increase digital defense budgets amid rising AI-powered threats.

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.

HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amplify Cybersecurity ETF

HACK provides diversified exposure to the global cybersecurity industry. It invests across the full value chain, including hardware, software, and consulting services, with key holdings in firms like Broadcom, Cisco, and Palo Alto Networks.

Read more on HACK

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX